Updates and Events
Catalyzing Research

First Lupus Nephritis Drug Approved In December of 2020, lupus research attained another major milestone-one which stemmed from a critical investigation funded by our organization. Now, with the FDA’s approval, belimumab (Benlysta®) can be used as a therapeutic for lupus nephritis. “An effective treatment developed specifically for lupus nephritis has been desperately needed,” commented Lupus […] READ MORE

Unraveling the Complexity of Lupus

New Strategic Plan Holds Great Promise The LRA has one purpose-to work on multiple fronts to improve the health of everyone with lupus through the power of science. Even with the unprecedented challenges of 2020, the LRA not only has remained true to this mission-the organization took a bold step forward with the launch of […] READ MORE

Meeting the Task Head-On: Addressing COVID-19

The Lupus Research Alliance would be remiss if we did not acknowledge the tremendous toll that COVID-19 has had on people across our country-especially people with underlying health concerns…like many in the lupus community. Today, there is much hope on the horizon and much that we can learn-and even gain-from this pandemic. For all the […] READ MORE

Unwavering in the Pursuit of Scientific Discovery A Snapshot of 2020’s Triumphs

Despite the uncertainty around COVID-19, the LRA was still able to jumpstart intriguing scientific investigations that hold the promise of making breakthroughs in treatment The LRA invested almost $11.5 million in research last year to continue to fund breakthrough projects in lupus. Here’s how: Seven world-renowned scientist received $2.1 million in grants through our Lupus […] READ MORE

A Message From Ken Farber

Dear Friends, I’m sure you agree—2020 was a year like no other. Yet, despite the challenges presented by COVID-19, the Lupus Research Alliance (LRA) managed – thanks to loyal supporters like you – to find creative solutions to keep the lupus community and our pioneering research where they belong: front and center I’m proud to […] READ MORE

Low-Dose Chemotherapy May Help Lupus Nephritis

February 22, 2021 In a recent study published in Arthritis & Rheumatology, LRA-funded researcher Dr. Xian Zhang found that a low dose of the chemotherapy drug topotecan reduced the inflammation and kidney damage of lupus nephritis in mice with lupus. Topotecan was as effective as high doses of cyclophosphamide, another chemotherapy that’s currently used to […] READ MORE

Join LRA’s Advocate for Lupus Research Week March 15 – 19, 2021

Your voices will be heard as loud and clear as ever, albeit virtually! Join us Monday, March 15 for our Advocate for Lupus Research meeting presented by PA Fund for Patient Advocacy at the LRA. Click here to join the virtual event. Hear from DC experts and experienced lupus advocates on how to advocate effectively and what we need Congress to […] READ MORE

Virtual Events Were Real-ly Successful!

While the pandemic made it impossible for the LRA to hold in person fundraising events, we still achieved great success thanks to the determination of our supporters to fund crucial lupus research. Likewise, our “virtual gala” – bolstered by superstars like Lady Gaga and Selena Gomez – raised an astounding $3.3 million and was attended […] READ MORE

LRA Shares Tremendous Loss of Lupus Research Hero Dr. Marc Chevrier

February 10, 2021 The worldwide lupus community lost a brilliant researcher and a passionate champion with the recent passing of rheumatologist Marc Chevrier, MD, PhD, FACR.  A larger-than-life personality with a huge heart to match, Dr. Chevrier was a devoted friend to hundreds of people with lupus and those who care for them.  Perhaps most […] READ MORE

New CDC Study Estimates 204,295 Americans Have Lupus

January 29, 2021 According to a new analysis funded by the Centers for Disease Control and Prevention, about 204,295 Americans have systemic lupus erythematosus (SLE), based on strict criteria for diagnosis by the American College of Rheumatology. These data, however, do not include cutaneous lupus. Based on an analysis of five studies, the national estimate […] READ MORE

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] READ MORE

Together, ManyOne Can make a difference!
Stay informed about events, research developments, and ways you can help. Sign up for updates